Welcome to our dedicated page for Acelyrin news (Ticker: SLRN), a resource for investors and traders seeking the latest updates and insights on Acelyrin stock.
ACELYRIN, Inc. (SLRN) is a late-stage biopharmaceutical innovator developing targeted therapies for autoimmune and inflammatory conditions. This news hub provides investors and healthcare professionals with essential updates on clinical milestones, regulatory developments, and strategic initiatives.
Access timely reports on izokibep and lonigutamab clinical trials, partnership announcements, and corporate updates. Our curated collection includes:
• Phase 2/3 clinical trial results
• Regulatory submissions and approvals
• Strategic collaborations and M&A activity
• Pipeline expansion announcements
Bookmark this page for centralized access to ACELYRIN's latest progress in advancing IL-17A inhibitors and IGF-1R targeted therapies. Check regularly for verified updates on treatments for psoriatic arthritis, thyroid eye disease, and other immune-mediated conditions.
ACELYRIN, INC. provided a business update, highlighting milestones such as completing enrollment in Phase 3 trials and reporting positive data for lonigutamab and izokibep. The company aims to accelerate the development of transformative medicines while maintaining financial stability. Changes in the leadership team were also announced.
ACELRYIN, INC. announced a leadership transition with Mina Kim appointed as the new CEO and board member, replacing founder Shao-Lee Lin, who stepped down. The company focuses on developing transformative medicines in immunology and has seen early positive data in clinical trials. Shep Mpofu becomes the Chief Medical Officer, Gil Labrucherie takes on the role of Chief Business Officer, in addition to being the CFO, and Sanam Pangali is named Chief Legal Officer and Head of People.
On May 13, 2024, ACELYRIN, INC. (SLRN) will host a conference call to discuss its first quarter 2024 financial results and corporate update. The company focuses on transformative medicines in immunology, with a live webcast and replay available on its website.
FAQ
What is the current stock price of Acelyrin (SLRN)?
What is the market cap of Acelyrin (SLRN)?
